Agile Therapeutics, Inc. (AGRX) EPS Estimated At $-0.25; Geode Capital Management Has Decreased Pharmerica (PMC) Stake By $2.91 Million

February 20, 2018 - By Louis Casey

Analysts expect Agile Therapeutics, Inc. (NASDAQ:AGRX) to report $-0.25 EPS on March, 14.They anticipate $0.04 EPS change or 13.79% from last quarter’s $-0.29 EPS. After having $-0.22 EPS previously, Agile Therapeutics, Inc.’s analysts see 13.64% EPS growth. The stock increased 1.10% or $0.04 during the last trading session, reaching $3.69. About 120,917 shares traded. Agile Therapeutics, Inc. (NASDAQ:AGRX) has declined 48.71% since February 20, 2017 and is downtrending. It has underperformed by 65.41% the S&P500.

Geode Capital Management Llc decreased Pharmerica Corp (PMC) stake by 26.35% reported in 2017Q3 SEC filing. Geode Capital Management Llc sold 100,479 shares as Pharmerica Corp (PMC)’s stock declined 5.51%. The Geode Capital Management Llc holds 280,880 shares with $8.23M value, down from 381,359 last quarter. Pharmerica Corp now has $ valuation. The stock decreased 100.00% or $29.2 during the last trading session, reaching $0. About 1.37 million shares traded or Infinity% up from the average. Pharmerica Corporation (NYSE:PMC) has declined 3.31% since February 20, 2017 and is downtrending. It has underperformed by 20.01% the S&P500.

Geode Capital Management Llc increased Usg Corp (NYSE:USG) stake by 22,176 shares to 725,925 valued at $23.70M in 2017Q3. It also upped Milacron Holdings Corp stake by 25,268 shares and now owns 390,848 shares. Novartis Ag (NYSE:NVS) was raised too.

Among 4 analysts covering Pharmerica (NYSE:PMC), 1 have Buy rating, 1 Sell and 2 Hold. Therefore 25% are positive. Pharmerica had 8 analyst reports since August 10, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Monday, August 10 by Barrington Research. The stock of Pharmerica Corporation (NYSE:PMC) earned “Neutral” rating by UBS on Monday, August 10. Barrington Research maintained Pharmerica Corporation (NYSE:PMC) on Tuesday, May 10 with “Outperform” rating. The rating was downgraded by Barrington Research to “Underperform” on Thursday, August 3. The stock of Pharmerica Corporation (NYSE:PMC) has “Hold” rating given on Monday, August 17 by Zacks. The rating was downgraded by UBS on Monday, March 14 to “Neutral”. The firm has “Hold” rating by Credit Suisse given on Friday, August 4. The firm has “Buy” rating given on Tuesday, June 7 by Bank of America.

Investors sentiment decreased to 1.14 in Q3 2017. Its down 0.18, from 1.32 in 2017Q2. It fall, as 26 investors sold PMC shares while 40 reduced holdings. 35 funds opened positions while 40 raised stakes. 26.50 million shares or 1.04% less from 26.78 million shares in 2017Q2 were reported. D E Shaw owns 326,593 shares. Ls Advisors Ltd Company stated it has 0% of its portfolio in Pharmerica Corporation (NYSE:PMC). Congress Asset Mngmt Com Ma owns 38,077 shares for 0.02% of their portfolio. Thrivent Finance For Lutherans accumulated 18,970 shares. Gamco Inc Et Al invested in 123,351 shares or 0.02% of the stock. 20,911 are held by Nationwide Fund Advsr. State Of Alaska Department Of Revenue reported 0.01% of its portfolio in Pharmerica Corporation (NYSE:PMC). 60,500 were accumulated by Havens Advsrs Ltd. Renaissance Tech Limited Liability Corporation has invested 0.01% in Pharmerica Corporation (NYSE:PMC). Omers Administration invested in 0.06% or 168,200 shares. Prudential Public Limited has 574,800 shares. Principal Fincl Gru owns 235,450 shares for 0.01% of their portfolio. Barclays Public Ltd Co holds 0% or 68,386 shares. Panagora Asset Mgmt stated it has 0% of its portfolio in Pharmerica Corporation (NYSE:PMC). Gabelli & Inv Advisers Inc holds 0.42% of its portfolio in Pharmerica Corporation (NYSE:PMC) for 123,444 shares.

Investors sentiment increased to 1.35 in Q3 2017. Its up 0.74, from 0.61 in 2017Q2. It is positive, as 9 investors sold Agile Therapeutics, Inc. shares while 8 reduced holdings. 11 funds opened positions while 12 raised stakes. 23.16 million shares or 7.44% more from 21.56 million shares in 2017Q2 were reported. Great Point Prtnrs Ltd Liability Corporation stated it has 363,299 shares or 0.32% of all its holdings. Deerfield Mgmt Comm holds 0.25% or 1.22 million shares. 30,769 were reported by Commonwealth Of Pennsylvania Pub School Empls Retrmt. Proquest Associates Iv Ltd Co reported 5.06 million shares. Pura Vida Invests Ltd Limited Liability Company has invested 0.65% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Virtu Ltd Company holds 0% of its portfolio in Agile Therapeutics, Inc. (NASDAQ:AGRX) for 83,806 shares. 2.77M are held by Franklin Resources. Parametric Port Limited Co owns 11,941 shares. Blackrock reported 108,891 shares stake. Janney Montgomery Scott Ltd Liability Corporation has invested 0% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Alyeska Investment Group L P reported 840,169 shares. Royal Bankshares Of Canada holds 135,820 shares. Endurant Cap Management Ltd Partnership holds 0.6% of its portfolio in Agile Therapeutics, Inc. (NASDAQ:AGRX) for 441,708 shares. Investor holds 1.01% or 3.51 million shares in its portfolio. New York-based Morgan Stanley has invested 0% in Agile Therapeutics, Inc. (NASDAQ:AGRX).

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $126.15 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Louis Casey

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: